Profile data is unavailable for this security.
About the company
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
- Revenue in USD (TTM)0.00
- Net income in USD-34.45m
- Incorporated1973
- Employees1.00
- LocationGT Biopharma Inc505 MONTGOMERY STREET, 10TH FLOORSAN FRANCISCO 94111United StatesUSA
- Phone+1 (310) 551-4020
- Fax+1 (302) 655-5049
- Websitehttps://www.gtbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Soligenix Inc | 0.00 | -11.46m | 11.50m | 14.00 | -- | 1.48 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.91m | 25.00 | -- | 1.18 | -- | 8.29 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 12.39m | 85.00 | -- | 2.64 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -34.45m | 12.52m | 1.00 | -- | 2.07 | -- | -- | -3.93 | -3.93 | 0.00 | 0.2266 | 0.00 | -- | -- | 0.00 | -459.62 | -172.68 | -1,377.41 | -460.87 | -- | -- | -- | -- | -- | -3,105.50 | 0.00 | -- | -- | -- | -161.73 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.82m | 82.00 | -- | 0.3684 | -- | 1.37 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 12.97m | -- | -- | 0.9074 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 13.00m | 1.00 | -- | 1.70 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| NewcelX AG | 0.00 | -6.21m | 13.04m | 1.00 | -- | 0.4213 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 13.18m | 7.00 | 0.0584 | 2.59 | -- | 4.63 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| BioCardia Inc | 0.00 | -8.54m | 13.48m | 17.00 | -- | 5.13 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Curis Inc | 11.65m | -36.56m | 13.60m | 33.00 | -- | -- | -- | 1.17 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 13.62m | 2.00 | -- | 1.73 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Bioatla Inc | 0.00 | -64.71m | 13.74m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Bristol Capital Advisors LLCas of 29 May 2025 | 150.00k | 4.22% |
| Citadel Securities LLCas of 31 Dec 2025 | 80.76k | 2.27% |
| Scientech Research LLCas of 31 Dec 2025 | 54.75k | 1.54% |
| SeaCrest Wealth Management LLCas of 31 Dec 2025 | 50.00k | 1.41% |
| Jane Street Capital LLCas of 31 Dec 2025 | 26.02k | 0.73% |
| Integrated Wealth Concepts LLCas of 31 Dec 2025 | 20.01k | 0.56% |
| Geode Capital Management LLCas of 31 Dec 2025 | 19.26k | 0.54% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 18.60k | 0.52% |
| Coston, McIsaac & Partners, Inc.as of 31 Dec 2025 | 17.09k | 0.48% |
| Caitlin John LLCas of 31 Dec 2025 | 16.50k | 0.46% |
